The Company expects full year 2024 XHANCE average net revenue per prescription to exceed $230. Previously the Company expected full year 2024 XHANCE average net revenue per prescription to be approximately $220. The Company expects total GAAP operating expenses for 2024 to be between $95.0 to $101.0 million, of which the Company expects stock-based compensation to be approximately $6.0 million. The Company expects to product positive income from operations for full year 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
- Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
- OPTN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Optinose Announces Reporting Date for First Quarter 2024 Financial Results
- Optinose sees FY24 XHANCE net revenue at $85M-$95M
- Optinose announces $55M registered direct offering at $1.00 per share